학술논문
Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years -- United States, July-December 2021.
Document Type
Article
Author
Zambrano, Laura D.; Newhams, Margaret M.; Olson, Samantha M.; Halasa, Natasha B.; Price, Ashley M.; Boom, Julie A.; Sahni, Leila C.; Kamidani, Satoshi; Tarquinio, Keiko M.; Maddux, Aline B.; Heidemann, Sabrina M.; Bhumbra, Samina S.; Bline, Katherine E.; Nofziger, Ryan A.; Hobbs, Charlotte V.; Bradford, Tamara T.; Cvijanovich, Natalie Z.; Irby, Katherine; Mack, Elizabeth H.; Cullimore, Melissa L.
Source
Subject
*MULTISYSTEM inflammatory syndrome in children
*COUGH
*COVID-19 vaccines
*VACCINATION
*CHILDREN'S hospitals
*DRUG efficacy
*IMMUNIZATION
*MULTISYSTEM inflammatory syndrome
*TREATMENT effectiveness
*MESSENGER RNA
*CHILDREN
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0149-2195
Abstract
The article informs that Pfizer-BioNTech vaccine, currently authorized for persons aged ≥5 years, provides a high level of protection against severe COVID-19 in persons aged 12–18 years. It is noted taht Vaccine effectiveness against multisystem inflammatory syndrome in children, which can occur 2–6 weeks after SARS-CoV-2 infection, has remained uncharacterized.